

21 March 2024

Bristol-Myers Squibb International Corporation

Email: mg-gsm-ct@bms.com

Chaussée de la Hulpe 185

Brussels, Belgium

1170

EudraCT Number: 2017-004896-30
Sponsor Protocol Number: CA224-051

A Randomized, Active-Controlled, Blinded, Phase III Clinical Trial of BMS- 986213 (Fixed Dose Combination of Relatlimab [anti-LAG-3] and Nivolumab) in Combination with Chemotherapy versus Placebo in Combination with Chemotherapy as First-Line Treatment in Participants with Unresectable, Locally Advanced or Metastatic LAG-3 Positive Gastric or Gastroesophageal Junction Adenocarcinoma

Trial (2017-004896-30) was withdrawn with 0 patients enrolled. Therefore, no results are reported.